LIBREXIA ACS
2026
A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome (Librexia ACS)
In 14,194 patients with a recent acute coronary syndrome, milvexian added to antiplatelet therapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with placebo.
Result
Efficacy: Time to first occurrence of the composite of cardiovascular death, myocardial infarction or ischaemic strokeHR 1.05 (95% CI 0.91-1.21) · P = 0.50
Safety: Intracranial or fatal bleedingHR 1.04 (95% CI 0.58-1.87) · P = 0.88
Below 1 favours milvexian added to antiplatelet therapy, above 1 favours placebo.
Event rates Milvexian added to antiplatelet therapy 5.4% vs placebo 5.1% (time to first occurrence of the composite of cardiovascular death, myocardial infarction or ischaemic stroke)
Also reported: Cardiovascular death, myocardial infarction or ischaemic stroke . Stopped for futility at the interim analysis in November 2025.
- Subtopic
- Factor XIa inhibition
- Design
- International, multicentre, randomised, double-blind (quadruple-masked), placebo-controlled, event-driven phase 3 trial; 1:1 allocation to milvexian or matched placebo on top of investigator-chosen standard antiplatelet therapy (SAPT or DAPT); randomisation stratified by planned type and duration of antiplatelet therapy; follow-up planned until 875 primary-endpoint events (up to about 3.5 years)
- Relevance
- Important: one of several pillars.
- Source
- Gibson CM, Steg PG, Bahit MC, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2608717
Discussion & critique
Factor XI inhibition promised the separation every antithrombotic programme is chasing: fewer events without more bleeding. In 14,194 patients after an acute coronary syndrome, milvexian delivered the second half and none of the first: identical bleeding, identical events, stopped for futility. The bleeding safety is real and matters for the atrial fibrillation and stroke programmes still running, but on top of modern antiplatelet therapy after ACS there was nothing left to prevent.